AdultPediatricGeriatricDosage Forms & Strengths tablet 10mg Major Depressive Disorder For use in patients who have not responded adequately to other antidepressants Not indicated for nitial treatment due to potential for serious adverse reactions and drug interactions, and need for dietary restrictions 15 mg PO q12hr Increase by 5 mg/dose at q1-3Weeks to optimum response; not to exceed 60 mg/day May slowly decrease dosage to maintain dose once response is adequate Dosing Considerations Consider discontinuing therapy gradually because of risk for withdrawal effects Switching from contraindicated antidepressants After stopping treatment with contraindicated antidepressants, a time period of 4-5 half-lives of other antidepressant or any active metabolite should elapse before starting therapy; after stopping treatment with an MAO inhibitor antidepressant, a time period of at least one week or 4-5 half-lives of other MAO inhibitor (whichever is longer) should elapse before starting treatment therapy to reduce risk of additive effects Switching from to other MAOIs or contraindicated antidepressants After stopping treatment, at least one week should elapse before starting another MAOI (intended to treat MDD) or other contraindicated antidepressants; refer to prescribing information of subsequently used drug for product-specific advice on a medication-free interval Discontinuing treatment Withdrawal effects, including delirium, reported with abrupt discontinuation therapy; higher daily doses and longer duration of use appear to be associated with a higher risk of withdrawal effects; consider discontinuing therapy by slow, gradual dosage reduction Safety & efficacy not establishedMajor Depressive Episode without Melancholia 15 mg PO q12hr Increase by 5 mg/dose at q1-3Weeks to optimum response; not to exceed 60 mg/day May slowly decrease dosage to maintain dose once response is adequateInteraction CheckerEnter a drug name and tranylcypromineNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (94)amitriptylinetranylcypromine and amitriptyline both increase serotonin levels. Contraindicated.amoxapinetranylcypromine and amoxapine both increase serotonin levels. Contraindicated.apraclonidineapraclonidine, tranylcypromine. Mechanism: unknown. Contraindicated. Contraindicated in mfr. prescribing info.tranylcypromine, apraclonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info.armodafiniltranylcypromine increases effects of armodafinil by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.atomoxetinetranylcypromine increases effects of atomoxetine by pharmacodynamic synergism. Contraindicated. The use of atomoxetine with monoamine oxidase inhibitors (MAOIs) is contraindicated. Risk of acute hypertensive episode.benzphetaminetranylcypromine increases effects of benzphetamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.brimonidinetranylcypromine, brimonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info.bupropiontranylcypromine and bupropion both increase dopaminergic effects. Contraindicated. Bupropion inhibits reuptake of dopamine and norepinephrine (NE), and MAOIs decrease metabolism of dopamine and NE; coadministration increases risk for hypertensive reactions; allow at least 14 days between discontinuation of MAOI and initiating bupropionbuspironetranylcypromine and buspirone both increase serotonin levels. Contraindicated.tranylcypromine, buspirone. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.caffeinetranylcypromine increases effects of caffeine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.carbamazepinecarbamazepine increases toxicity of tranylcypromine by unknown mechanism. Contraindicated. D/C MAO inhibitor 2 weeks before.citalopramtranylcypromine and citalopram both increase serotonin levels. Contraindicated. At least 2 weeks should elapse between discontinuation of MAOI therapy and the start of citalopram therapy, and at least 2 weeks between discontinuation of citalopram therapy and commencement of MAOI therapy.clomipraminetranylcypromine and clomipramine both increase serotonin levels. Contraindicated.cyclobenzaprinetranylcypromine and cyclobenzaprine both increase serotonin levels. Contraindicated. Do not coadminister cyclobenzaprine with MAOIs or within 14 days of discontinuing an MAOIcyproheptadinetranylcypromine, cyproheptadine. Other (see comment). Contraindicated. Comment: MAO inhibitors may prolong and intensify the anticholinergic effects of antihistamines. Cyproheptadine may diminish the serotonergic effect of MAO inhibitors.desipraminetranylcypromine and desipramine both increase serotonin levels. Contraindicated.desvenlafaxinetranylcypromine and desvenlafaxine both increase serotonin levels. Contraindicated. At least 14 days should elapse between discontinuation of MAOIs and initiation of treatment with a serotonergic drugdeutetrabenazinetranylcypromine, deutetrabenazine. Either increases toxicity of the other by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Contraindicated. Deutetrabenazine should not be used in combination with an MAOI, or within 14 days of discontinuing therapy with an MAOI.dexfenfluraminetranylcypromine increases effects of dexfenfluramine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.dexmethylphenidatetranylcypromine increases effects of dexmethylphenidate by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.dextroamphetaminetranylcypromine increases effects of dextroamphetamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.dextroamphetamine transdermaltranylcypromine increases effects of dextroamphetamine transdermal by decreasing metabolism. Contraindicated. MAOIs slows amphetamine metabolism, increasing amphetamine?s effect on norepinephrine release and other monoamines from adrenergic nerve endings causing signs of hypertensive crisis. Do not administer dextroamphetamine during or within 14 days following MAOI administration.dextromethorphantranylcypromine and dextromethorphan both increase serotonin levels. Contraindicated.diethylpropiontranylcypromine increases effects of diethylpropion by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.dobutaminetranylcypromine increases effects of dobutamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.dopaminetranylcypromine increases effects of dopamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.dosulepintranylcypromine and dosulepin both increase serotonin levels. Contraindicated.doxepintranylcypromine and doxepin both increase serotonin levels. Contraindicated.duloxetinetranylcypromine and duloxetine both increase serotonin levels. Contraindicated.eliglustattranylcypromine increases levels of eliglustat by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. If coadministered with strong or moderate CYP2D6 inhibitors, reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive and intermediate metabolizers; eliglustat is contraindiated if strong or moderate CYP2D6 inhibitors are given concomitantly with strong or moderate CYP3A inhibitors.entacaponeentacapone, tranylcypromine. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Both nonselective MAO inhibitors and entacapone inhibit catecholamine metabolism, leading to increased levels of catecholamines. Potential for dangerously high HR or BP.ephedrinetranylcypromine increases effects of ephedrine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.epinephrinetranylcypromine increases effects of epinephrine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.epinephrine inhaledtranylcypromine and epinephrine inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Contraindicated. Coadministration of epinephrine inhaled with MAOIs or within 2 weeks after discontinuing an MAOI is contraindicated.escitalopramtranylcypromine and escitalopram both increase serotonin levels. Contraindicated.fenfluraminetranylcypromine increases effects of fenfluramine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.fenfluramine, tranylcypromine. Either increases effects of the other by serotonin levels. Contraindicated. Coadministration with drugs that increase serotonin may increase the risk of serotonin syndrome. Do not use concomitantly or within 14 days of MAOIs.fentanyltranylcypromine increases toxicity of fentanyl by Other (see comment). Contraindicated. Comment: Avoid fentanyl in patients who require concomitant administration MAOIs, or within 14 days of stopping an MAOI. Severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics.fentanyl intranasaltranylcypromine increases toxicity of fentanyl intranasal by Other (see comment). Contraindicated. Comment: Avoid fentanyl in patients who require concomitant administration MAOIs, or within 14 days of stopping an MAOI. Severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics.fentanyl transdermaltranylcypromine increases toxicity of fentanyl transdermal by Other (see comment). Contraindicated. Comment: Avoid fentanyl in patients who require concomitant administration MAOIs, or within 14 days of stopping an MAOI. Severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics.fentanyl transmucosaltranylcypromine increases toxicity of fentanyl transmucosal by Other (see comment). Contraindicated. Comment: Avoid fentanyl in patients who require concomitant administration MAOIs, or within 14 days of stopping an MAOI. Severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics.fezolinetanttranylcypromine will increase the level or effect of fezolinetant by affecting hepatic enzyme CYP1A2 metabolism. Contraindicated. Fezolinetant AUC and peak plasma concentration are increased if coadministered with drugs that are weak, moderate, or strong CYP1A2 inhibitorsfluoxetinetranylcypromine and fluoxetine both increase serotonin levels. Contraindicated.imipraminetranylcypromine and imipramine both increase serotonin levels. Contraindicated.isocarboxazidisocarboxazid and tranylcypromine both increase serotonin levels. Contraindicated.isometheptenetranylcypromine, isometheptene. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Hypertension, V tach.isoproterenoltranylcypromine increases effects of isoproterenol by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.levodopatranylcypromine, levodopa. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.levodopa inhaledlevodopa inhaled increases effects of tranylcypromine by dopaminergic effects. Contraindicated. Levodopa may enhance risk for acute hypertensive episode if coadministered with nonselective MAOIs. Discontinue use of any nonselective MAO inhibitors at least 2 weeks before initiating levodopa inhaled.levomilnaciprantranylcypromine and levomilnacipran both increase serotonin levels. Contraindicated. Do not use MAOIs intended to treat psychiatric disorders with levomilnacipran or within 7 days of stopping levomilnacipran due to an increased risk of serotonin syndromelisdexamfetaminetranylcypromine, lisdexamfetamine. Either increases effects of the other by serotonin levels. Contraindicated. Do not use amphetamines during and within 14 days of discontinuation of monoamine oxidase inhibitors. .lofepraminetranylcypromine and lofepramine both increase serotonin levels. Contraindicated.maprotilinetranylcypromine and maprotiline both increase serotonin levels. Contraindicated.mavacamtentranylcypromine will increase the level or effect of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. meperidinetranylcypromine and meperidine both increase serotonin levels. Contraindicated.tranylcypromine increases toxicity of meperidine by unknown mechanism. Contraindicated.methamphetaminetranylcypromine increases effects of methamphetamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.methylenedioxymethamphetaminetranylcypromine increases effects of methylenedioxymethamphetamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.methylphenidatetranylcypromine increases effects of methylphenidate by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI.methylphenidate transdermalmethylphenidate transdermal and tranylcypromine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Contraindicated. Coadministration of MAOIs and CNS stimulants can cause hypertensive crisis.midodrinetranylcypromine increases effects of midodrine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.milnaciprantranylcypromine and milnacipran both increase serotonin levels. Contraindicated.modafiniltranylcypromine increases effects of modafinil by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.nefazodonetranylcypromine and nefazodone both increase serotonin levels. Contraindicated.norepinephrinetranylcypromine increases effects of norepinephrine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.nortriptylinetranylcypromine and nortriptyline both increase serotonin levels. Contraindicated.opicaponeopicapone, tranylcypromine. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Both nonselective MAO inhibitors and opicapone inhibit catecholamine metabolism, leading to increased levels of catecholamines. Potential for dangerously high HR or BP.ozanimodtranylcypromine and ozanimod both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Contraindicated. Coadministration of ozanimod with MAO-B inhibitors may decrease exposure of the active metabolites of ozanimod, which may inhibit MAO. The potential for a clinical interaction with MAO inhibitors has not been studied; however, the increased risk of nonselective MAO inhibition may lead to a hypertensive crisis. Allow at least 14 days to elapse between discontinuing ozanimod and initiating with MAO inhibitors.paroxetinetranylcypromine and paroxetine both increase serotonin levels. Contraindicated.phendimetrazinetranylcypromine increases effects of phendimetrazine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.phenelzinephenelzine and tranylcypromine both increase serotonin levels. Contraindicated.phenterminetranylcypromine increases effects of phentermine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.phenylephrinetranylcypromine increases effects of phenylephrine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.phenylephrine POtranylcypromine increases effects of phenylephrine PO by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.procarbazineprocarbazine and tranylcypromine both increase serotonin levels. Contraindicated. At least 2 weeks should elapse between discontinuation of one MAOI and initiation of therapy with the other.propylhexedrinetranylcypromine increases effects of propylhexedrine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.protriptylinetranylcypromine and protriptyline both increase serotonin levels. Contraindicated.pseudoephedrinetranylcypromine increases effects of pseudoephedrine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.rasagilinerasagiline and tranylcypromine both increase serotonin levels. Contraindicated. At least 14 days should elapse between discontinuation of rasagiline and initiation of another MAOI or discontinuation of another MAOI and initiation of rasagiline.safinamidetranylcypromine, safinamide. Either increases toxicity of the other by serotonin levels. Contraindicated. Coadministration increases risk of nonselective MAO inhibition, that may lead to hypertensive crisis. At least 14 days should elapse between discontinuating safinamide and initiating MAOIs.selegilineselegiline and tranylcypromine both increase serotonin levels. Contraindicated.selegiline transdermalselegiline transdermal and tranylcypromine both increase serotonin levels. Contraindicated.serdexmethylphenidate/dexmethylphenidatetranylcypromine increases effects of serdexmethylphenidate/dexmethylphenidate by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.sertralinetranylcypromine and sertraline both increase serotonin levels. Contraindicated.solriamfetoltranylcypromine will increase the level or effect of solriamfetol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Contraindicated. Do no use solriamfetol during and/or within 14 days of discontinuing MAOI treatment. MAOIs irreversibly inhibit the enzyme monamine oxidase, an enzyme involved in the degradation of various monoamines, including dopamine and norepinephrine. Solriamfetol increases synaptic dopamine and norepinephrine.St John's Worttranylcypromine and St John's Wort both increase serotonin levels. Contraindicated.tetrabenazinetetrabenazine, tranylcypromine. Other (see comment). Contraindicated. Comment: Risk of acute hypertensive episode; separate by 14 d. Mechanism: MAOI causes accumulation of NE in neuron and tetrabenazine stimulates NE release.tolcaponetolcapone, tranylcypromine. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Both nonselective MAO inhibitors and tolcapone inhibit catecholamine metabolism, leading to increased levels of catecholamines. Potential for dangerously high HR or BP.trazodonetranylcypromine and trazodone both increase serotonin levels. Contraindicated.trimipraminetranylcypromine and trimipramine both increase serotonin levels. Contraindicated.tyraminetranylcypromine increases effects of tyramine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode. Tyramine containing foods